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Summary
We demonstrate thatDNp63a is an essential survival factor in head and neck squamous cell carcinoma (HNSCC) through its
ability to suppress p73-dependent apoptosis. Inhibition of endogenous p63 expression by RNAi induces apoptosis selec-
tively in HNSCC cells that overexpress DNp63a. Knockdown of p63 induces the proapoptotic bcl-2 family members Puma
and Noxa, and both their induction and subsequent cell death are p53 independent but require transactivating isoforms
of p73. Inhibition of p73-dependent transcription by DNp63a involves both direct promoter binding and physical interaction
with p73. In HNSCC cells lacking endogenous DNp63a expression, bcl-2 is instead upregulated and can suppress p73-
mediated death. Together, these data define a pathway whereby DNp63a promotes survival in squamous epithelial malig-
nancy by repressing a p73-dependent proapoptotic transcriptional program.Introduction
Apoptosis represents a fundamental roadblock to tumorigene-
sis. During tumor formation, genome instability, oncogenic
stress, hypoxia, and other stresses trigger the apoptotic re-
sponse (Lowe et al., 2004; Vogelstein and Kinzler, 2004). Inacti-
vation of pathways mediating apoptosis is therefore essential to
nascent tumor cells. One common mechanism for disabling
apoptosis involves inactivation of p53, the prototypical tumor
suppressor that is mutated in more than 50% of human cancers
(Vogelstein et al., 2000; Vousden, 2000). Indeed, recent data
from model organisms has demonstrated directly that loss of
p53-mediated apoptosis, rather thanother p53-dependent func-
tions, is the critical target of selection during tumor formation
(Schmitt et al., 2002).
Like p53, the p53 family member p73 is known to be an impor-
tant mediator of apoptosis in response to DNA damage, chemo-
therapy, and other stimuli (Gong et al., 1999; Irwin et al., 2003;
Urist et al., 2004; Yuan et al., 1999). Nevertheless, mutation of
p73 is not observed at a significant frequency in human cancers
(Melino et al., 2003; Moll and Slade, 2004). Instead, recent evi-
dence suggests that other mechanisms may contribute to func-
tional inactivation of p73 in human tumors. These include pro-
moter methylation, overexpression of inhibitory isoforms ofCANCER CELL 9, 45–56, JANUARY 2006 ª2006 ELSEVIER INC. DOI 10.1p73 itself, and interaction with a subset of mutant p53 proteins
(Bergamaschi et al., 2003; Chim et al., 2002; Gaiddon et al.,
2001; Irwin et al., 2003; Zaika et al., 2002). These findings sup-
port the notion that inhibition of p73 function may be critical to
the pathogenesis of some human tumors.
Head and neck squamous cell carcinomas (HNSCC) repre-
sent a group of treatment-refractory malignancies derived
from cells within the basal epithelia of the aerodigestive mucosa
(Forastiere et al., 2001). A common molecular abnormality ob-
served in these tumors is overexpression of the p53 family mem-
ber p63. Numerous studies have documented increased p63
expression in up to 80%of primary HNSCC tumors, and its over-
expression is also commonly observed in other squamous epi-
thelial malignancies, including lung and esophagus (Hu et al.,
2002; Massion et al., 2003; Sniezek et al., 2004; Weber et al.,
2002). p63 maps to chromosome 3q27-28, and human squa-
mous cell carcinomas (SCCs) frequently exhibit genomic ampli-
fication at 3q (Bjorkqvist et al., 1998). The relevance of these
observations is supported by data showing that increased
p63mRNA levels correlate with increased p63 gene copy num-
ber in SCCs of the lung and head and neck (Hibi et al., 2000;
Tonon et al., 2005). In some cases, overexpression of p63 is
likely to involve mechanisms independent of genomic amplifi-
cation (Redon et al., 2001). In either case, it is apparent thatS I G N I F I C A N C E
Genomic amplification and/or overexpression of the p53 family member p63 is commonly observed in HNSCC, yet the precise con-
tribution of p63 in tumor cells remains uncertain. While some studies have posited thatDNp63amight inhibit p53 function within cancer
cells, this model is challenged by the lack of consistent correlation between p53mutation and p63 expression in these tumors. The p73
protein is thought to exert a proapoptotic function, yet unlike p53,p73 is not targeted formutation in HNSCC. Here, we demonstrate that
endogenousDNp63apromotes survival of HNSCCcells by repressing p73-dependent apoptosis. These findings provide an explanation
for p63 overexpression in HNSCC, and they represent direct evidence for inhibitory interactions between endogenous p63 and p73.016/j.ccr.2005.12.013 45
A R T I C L Eoverexpression of p63 is one of themost commonmolecular ab-
normalities identified in HNSCC. Nevertheless, the precise con-
tribution of p63 overexpression to HNSCC remains undefined.
The essential function of p63 in the epithelium is evidenced by
the phenotype of p63 null mice, which exhibit profound develop-
mental failure of the epidermis and oral epithelium, as well as
abnormalities of limb, prostate, and mammary development
(Mills et al., 1999; Yang et al., 1999). Like p53 and p73, p63 is a
sequence-specific DNA binding factor that regulates transcrip-
tion of critical downstream target genes. All three p53 family
members possess a highly homologous DNA binding domain,
through which they regulate a shared subset of transcriptional
targets (Harms et al., 2004). Expression from two distinct p63
promoters produces protein isoforms that either contain or
lack the N-terminal transactivation domain (TAp63 and DNp63,
respectively). Differential mRNA splicing also gives rise to multi-
ple C-terminal variants (Yang et al., 1998). In both normal epithe-
lia and in HNSCC cells, the predominant p63 isoform expressed
is DNp63a (Parsa et al., 1999; Yang et al., 1998). While few bona
fide transcriptional target genes of p63 have been identified,
DNp63a is known to function as a transcriptional repressor of
endogenous cell cycle inhibitors including p21CIP1, implying a
contribution by p63 to cellular proliferation (Westfall et al.,
2003). Other studies have proposed roles for p63 in cell survival,
cellular differentiation, and morphogenesis (King et al., 2003;
Mills et al., 1999; Yang et al., 1999).
In addition to its role in normal epithelia, DNp63a has been hy-
pothesized to contribute to tumorigenesis based on its ability to
inhibit p53-dependent transactivation in vitro following ectopic
expression of these proteins (King et al., 2003; Yang et al.,
1998). Such observations supported a model whereby overex-
pression of p63 might inactivate p53, therefore abrogating the
requirement for its loss during tumorigenesis. Whether these
findings reflect an endogenous function of p63 remains uncer-
tain, since no consistent correlation has been proven between
p53 mutation and p63 overexpression in SCCs (Choi et al.,
2002; Hibi et al., 2000; Sniezek et al., 2004; Weber et al., 2002).
Similarly, although ectopic DNp63a expression can block p73-
dependent reporter transactivation, and p73 and p63 associate
in cotransfection assays (Chan et al., 2004), it remains to be
determined whether endogenous p63 exhibits either a physical
or functional interaction with p73 in tumor cells. Indeed, it has
been proposed that p63 promotes oncogenesis in HNSCC cells
by a distinct mechanism involving enhancement of b-catenin-
dependent transcription (Patturajan et al., 2002). Thus, the con-
tribution of any potential interaction between p63 and other p53
family members in SCC remains to be defined.
We wished to focus on the role of endogenous p63 in SCC.
We find that HNSCC-derived cell lines, like the majority of pri-
mary tumors, exhibit overexpression of both DNp63a mRNA
and protein relative to normal primary epidermal cells, and we
demonstrate that this p63 isoform promotes survival of HNSCC
cells by virtue of its ability to suppress a p73-dependent pro-
apoptotic transcriptional program.
Results
Expression of p63 isoforms in HNSCC cells
Numerous studies have used immunohistochemical analysis to
demonstrate overexpression of p63 protein in SCCs of the head
and neck, lung, and esophagus. Few studies have examined the46expression of multiple p63 isoforms in a quantitative manner.
We have used human HNSCC-derived cell lines as a model to
explore the function and biochemical mechanisms of p63.
These squamous carcinoma lines are derived from primary tu-
mors, are growth factor independent, and have been character-
ized for the most common genetic abnormalities present in
HNSCC (Richtsmeier and Carey, 1987; Scher et al., 1993). We
chose two representative cell lines that differ in their p53 status
for our analysis. JHU-029 expresses wild-type p53 as demon-
strated by functional and mutational analysis (Figure 5A, below,
and data not shown). In contrast, JHU-011 expresses only trun-
cated mutant p53 (Hoque et al., 2003), resulting from a splice
donor mutation following exon 6 (Figure S1 in the Supplemental
Data available with this article online). We first compared the
level of p63 expression in these cell lines to that observed in pri-
mary human epidermal keratinocytes (HK). As a control, we ex-
amined p63 expression in the human osteosarcoma-derived line
Saos-2, which is reported not to express p63 (Hibi et al., 2000).
ByWestern analysis, p63 is expressed in JHU-029 and JHU-011
at three to five times the level observed in normal HK (Figure 1A).
The size of the predominant p63 band detected corresponds to
the DNp63a isoform, consistent with prior studies showing
DNp63a to be the major isoform expressed in both normal and
malignant epithelial tissues (Parsa et al., 1999; Sniezek et al.,
2004). To extend and quantitate these results, we performed
isoform-specific real-time quantitative RT-PCR (QRT-PCR) to
detect isoforms containing or lacking the N-terminal transacti-
vation domain (TAp63 and DNp63, respectively). As anticipated,
DNp63 mRNA is overexpressed in HNSCC cells to the same de-
gree as its protein product, ranging in abundance from 3.5 to
8 times that observed in primary HK (Figure 1B). TAp63 mRNA
is rare in all cells tested, and in all cases DNp63 mRNA is
Figure 1. p63 is overexpressed in HNSCC cells
A: Immunoblot for p63 protein in cultured human keratinocytes (HK), two
HNSCC-derived cells lines (JHU-029, JHU-011), and the p63-negative line
Saos-2. The predominant band detected corresponds to DNp63a. b tubulin
(b-tub) serves as a loading control.
B: Levels of DNp63 mRNA correlate with those of DNp63a protein (A). Real-
time QRT-PCR was used to assay DNp63 mRNA levels, which are shown nor-
malized to GAPDH expression. The DNp63 mRNA level in HK is arbitrarily des-
ignated as 1.0.
C: DNp63 is highly expressed relative to TAp63. The ratio of DN/TAp63 mRNA
was determined by real-time QRT-PCR.
Error bars for B and C represent the standard deviation of three indepen-
dent experiments.CANCER CELL JANUARY 2006
A R T I C L EFigure 2. Inhibition of p63 by RNAi
A: p63-directed RNAi does not inhibit p53 or p73
expression. Immunoblot of lysates from Saos-2
cells following cotransfection of the indicated
p53 family member with plasmids expressing
either of two independent p63-directed shRNA
constructs (p63si-1,2), a nonspecific shRNA
(si-NS), or the control vector.
B: Inhibition of endogenous p63 expression in
HNSCC cells by lentiviral RNAi. Immunoblot of
lysates harvested 48 hr following infection with
the indicated lentiviral RNAi construct or the
control vector. Note that cells are propagated
in the absence of drug selection.
C:Quantitation of endogenous p63 inhibition by
lentiviral RNAi. Real-time QRT-PCR was used to
examine DNp63 mRNA levels in samples treated
as in B. Levels were normalized toGAPDH expres-
sion. The level in each vector-treated sample is
designated as 1.0. Error bars represent the stan-
dard error of three independent experiments.more than 100-fold more abundant than TAp63 mRNA (Fig-
ure 1C). This observation is consistent with our inability to detect
TAp63 protein isoforms byWestern analysis in either primary HK
or HNSCC cells (data not shown). As expected, Saos-2 ex-
presses no detectable p63 mRNA or protein (Figures 1A and
1B). Thus, DNp63a is the predominant p63 isoform expressed
in HNSCC cells.
RNAi-mediated inhibition of p63
In order to determine the functional role of endogenous p63 in
HNSCC cells, we used an RNAi (RNA-mediated interference)
approach. We designed multiple constructs expressing p63-
targeted small hairpin RNA (shRNA) species from the U6 RNA
Pol III promoter (Sui et al., 2002). We first tested the ability of
these shRNA species to inhibit expression of DNp63a in a co-
transfection assay. Two independent shRNA species efficiently
inhibited DNp63a expression, while the control U6 promoter
vector and a nonspecific shRNA species had no effect (Fig-
ure 2A). Importantly, none of these shRNA species inhibited ex-
pression of p53 or p73 (Figure 2A).
To efficiently inhibit endogenous p63, we created lentiviral
vectors expressing these shRNA species. We were able to opti-
mize lentiviral production and infection conditions in order to
ensure essentially 100% infection of JHU-029, JHU-011, and
Saos-2 cells, as assessed initially by using viruses coexpressing
either a puromycin resistance gene or a GFP protein (data not
shown). Importantly, this high infection efficiency allowed us to
carry out subsequent experiments on lentiviral-infected cell
populations in the absence of drug or other selection. Under
these conditions, we observed approximately 80% knockdown
of endogenousDNp63a protein andmRNA in both JHU-029 and
JHU-011, as assessed by Western analysis (Figure 2B), and by
real-time QRT-PCR (Figure 2C), respectively. Of note, the effi-
cacy of the two p63-directed shRNA species for p63 knock-
down is comparable (Figures 2B and 2C). Infection with a non-
specific shRNA species did not affect endogenous p63 protein
or mRNA levels (Figures 2B and 2C, respectively).CANCER CELL JANUARY 2006Induction of apoptosis following p63 inhibition
No significant effects on cell viability were observed at early time
points (24–36 hr) following infection with a p63-directed shRNA
lentivirus in JHU-029 or JHU-011 cells. However, between 48
and 72 hr a significant fraction of both JHU-029 and JHU-011
cells underwent obvious death and ultimately detached (Figures
3A and 3D). Cell death was accompanied by cleavage of the
poly(ADP-ribosylating) enzyme PARP-1, a specific hallmark of
apoptotic cell death (Figure 3A). In contrast, infection of either
cell line with the lentiviral vector or a nonspecific shRNA lentivi-
rus did not alter p63 expression, induce PARP cleavage, or
cause cell death (Figures 3A and 3D). As an additional control
for specificity, we infected Saos-2 cells (which do not express
p63) with a p63-directed lentiviral shRNA. Neither PARP cleav-
age nor cell deathwas observed under these conditions (Figures
3A and 3D).
To quantitate the fraction of apoptotic cells, we stained
unfixed cells 96 hr following lentiviral infection with annexin
V/propidium iodide (PI) and performed flow cytometry analysis.
This assay detects both early apoptotic (annexin V-positive/
PI-negative) and late apoptotic (annexin V-positive/PI-positive)
cells (Martin et al., 1995). Figure 3B shows representative an-
nexin V/PI profiles, and the data are summarized for all cell lines
in Figure 3C. Approximately one-third of JHU-029 and JHU-011
cells underwent apoptosis within 96 hr of infection with the p63-
specific shRNA lentivirus (Figures 3B and 3C). Similar results
were obtained using either of the two p63-directed shRNA spe-
cies, supporting the specificity of this effect (Figures 3B and 3C).
As above, no increase in cell death was observed following in-
fection of either cell line with the control lentiviral vector or non-
specific lentiviral shRNA. As expected, no death was observed
in Saos-2 following infection with any of these vectors (Fig-
ure 3C). Thus, specific inhibition of p63 triggers apoptotic cell
death in tumor cells in which it is expressed.
As noted above, the most abundant p63 protein present
within HNSCC cells is DNp63a. Thus, we reasoned that the
p63-mediated survival effect that we observe should be attrib-
uted primarily to expression of this p63 isoform. To test this47
A R T I C L EFigure 3. Inhibition of endogenous p63 by RNAi induces apoptosis in HNSCC cells
A: Knockdown of p63 induces PARP cleavage in HNSCC cells. Immunoblots of lysates harvested at the indicated times following infection with a p63 shRNA-
expressing lentivirus (p63si) or the control vector. Infection with the p63si lentivirus does not induce PARP cleavage in Saos-2, which does not express p63.
B: Induction of apoptosis in JHU-029 cells following infection with either p63-directed shRNA (p63si-1,2), but not with a nonspecific shRNA (si-NS) or the vector
control. Unfixed cells were stained with annexin V and propidium iodide (PI) 96 hr following infection with the indicated lentivirus, then analyzed by flow cy-
tometry. Numbers refer to the percent annexin V- and/or PI-positive cells (UL + UR + LR quadrants) in this representative experiment.
C: Apoptosis in HNSCC cells is specific to p63 RNAi. Quantitation of apoptotic cells (annexin V- and/or PI-positive) treated and analyzed as in B. The mean
values of three independent experiments for each cell line are shown. Error bars represent one standard deviation.
D: Loss of HNSCC cells following infection with the p63si lentivirus compared with the control vector. Representative fields were photographed 72 hr following
lentiviral infection. Saos-2 cells are unaffected by the p63si lentivirus. As above, cells are propagated in the absence of drug selection.possibility directly, we examined the effect of p63 knockdown in
JHU-029 cells expressing a shRNA-resistant DNp63a. The
amino acid sequence of the human andmurineDNp63a proteins
is highly conserved, but murine DNp63a is insensitive to our
human p63-directed shRNA by virtue of a nucleotide sequence
difference in the targeted region. We therefore used retroviral
transduction to establish pools of cells expressing murine
DNp63a or the control retroviral vector, followed by lentiviral
shRNA expression. We found that constitutive DNp63a expres-
sion substantially blocked PARP cleavage and cell death follow-
ing knockdown of endogenous p63 (Figures S2A and S2B).48Together, these data demonstrate that DNp63a functions to
promote the survival of HNSCC cells.
Apoptosis following p63 inhibition involves induction
of Puma and Noxa
In normal epithelia, DNp63a is known to function as a transcrip-
tional repressor of cell cycle regulatory genes that are positively
regulated by p53 (Westfall et al., 2003). In addition, DNp63a has
been implicated based on cotransfection studies as a repressor
of p73-dependent transcription (Chan et al., 2004; Yang et al.,
1998). Therefore, we hypothesized that in tumor cells p63 mightCANCER CELL JANUARY 2006
A R T I C L EFigure 4. Inhibition of endogenous p63 in HNSCC
cells induces Puma and Noxa
A: Induction of Puma and Noxa mRNA follow-
ing p63 RNAi. Real-time QRT-PCR for candi-
date proapoptotic genes was performed at the
indicated times following infection with a p63
shRNA-expressing lentivirus. Values shownare rel-
ative to infectionwith the control lentiviral vector
and normalized to GAPDH expression. Error bars
represent the standard error of three indepen-
dent experiments.
B: Inductionof PumaproteincorrelateswithPARP
cleavage and is specific to p63 inhibition. Immu-
noblot of lysates from JHU-029 cells infected with
lentivirus expressing either of two independent
p63-directed shRNAconstructs (p63si-1,2), anon-
specific shRNA (si-NS), or the control vector, har-
vested at the indicated times.
C: Induction of Pumaprotein following p63 inhibi-
tion correlates with PARP cleavage in JHU-011.
Immunoblot of lysates from cells treated as in B.
Saos-2 cells exhibit neither PARP cleavage nor
Puma induction following lentiviral infection.promote survival through either direct or indirect repression of
proapoptotic genes regulated by p53 or p73. We initially as-
sayed expression of the proapoptotic genes Bax, Noxa, Perp,
Puma, and AIP1 in JHU-029 by QRT-PCR following p63 RNAi.
Consistently, both Puma and Noxa but not other proapoptotic
geneswere induced by p63-directed RNAi (Figure 4A). Induction
of Puma mRNA and protein were detectable in both JHU-029
and JHU-011 cells within 48 hr, which is the earliest time at
which we observe PARP cleavage (Figures 4B and 4C). Noxa in-
duction occurs somewhat later, as the mRNA and protein were
both detectable within 72 hr (Figures 4A and 5B, respectively).
No induction of Puma or Noxa was observed following infection
with the lentiviral vector or the nonspecific shRNA. In addition,
neither gene was induced in Saos-2 following infection with ei-
ther the control or the p63 shRNA lentivirus (Figures 4B and
4C and data not shown). Thus, specific inhibition of p63 in
HNSCC cells leads to induction of proapoptotic effector genes,
PARP cleavage, and cell death. These findings imply that p63
expression is essential for survival of HNSCC cells due to its
suppression of a proapoptotic transcriptional program.
Cell death and Puma/Noxa induction following p63
inhibition require p73 but not p53 function
Both p53 and p73 have been identified as regulators of Puma
and Noxa transcription (Melino et al., 2004; Nakano and Vous-
den, 2001; Oda et al., 2000; Yu et al., 2001). Therefore, we
wished to determine whether p63-mediated repression of these
genes and cell death involved a functional interaction with en-
dogenous p53 or p73. Both JHU-029 and JHU-011 exhibit
induction of Puma, Noxa, and cell death following p63 knock-
down. Since JHU-011 is effectively p53 null (lacking expression
of either wild-type or stabilized mutant p53), it appeared that
p63 represses the apoptotic program through a mechanism
other than inhibition of p53 function. To address this issue in
an isogenic setting, we blocked p53 function in JHU-029 cellsCANCER CELL JANUARY 2006and then tested the effect of p63 knockdown. JHU-029 cells
were infected with a retrovirus encoding a C-terminal truncated
p53 fragment (p53DD) that is well characterized as a potent
dominant inhibitor of p53 function (Bowman et al., 1996). Impor-
tantly, this protein, like wild-type p53, does not physically inter-
act with endogenous p63 or p73 in HNSCC cells (data not
shown). To demonstrate p53 inactivation by p53DD in JHU-
029, we first examined expression of the p53-regulated gene
p21CIP1 following DNA damage by doxorubicin treatment, which
is known to elicit p53-dependent transcription (Lowe et al.,
1993). We found that p21CIP1 was induced in control JHU-029
cells following doxorubicin treatment, but not in JHU-029 cells
expressing p53DD (Figure 5A). Next, we infected these cells
with p63-directed or control lentiviral shRNA. We observed no
effect of p53DD expression on the p63-dependent induction
of Puma or Noxa (Figure 5B). In addition, p53DD expression
had no effect on cell death following p63 knockdown, as
assessed by annexin V/PI staining (Figure 5E). Together, these
data suggest that p53 does not contribute to the apoptotic pro-
gram induced following loss of p63.
In some cellular contexts, p73 promotes apoptosis by activat-
ing a subset of p53-regulated proapoptotic genes (Melino et al.,
2004). Therefore, we asked whether DNp63a might promote
survival through inhibition of p73 function. We first tested the
ability of p73 to regulate the expression of Puma and Noxa in
JHU-029 cells. We found that retroviral expression of p73 in-
duced both Puma and Noxa relative to control vector-infected
cells, and that both genes were further induced following treat-
ment of cells with lentiviral p63-directed shRNA (Figure 5C).
Thus, overexpression of p73 in HNSCC cells opposes the spe-
cific repressive effect of p63, and simultaneous p73 overexpres-
sion and p63 knockdown leads to the highest induction of pro-
apoptotic genes.
We next examined expression of endogenous p73 in JHU-
029. Using isoform-specific QRT-PCR, we detected expression49
A R T I C L Eonly of TAp73 isoforms and not DNp73 isoforms (data not
shown). Western analysis demonstrates that the major detect-
able p73 species corresponds in its migration to TAp73b
Figure 5. Puma and Noxa induction and cell death following p63 inhibition
are p53 independent but require transactivating p73 isoforms
A: Inhibition of p53 function by the dominant-negative p53DD. Immunoblot
of lysates from JHU-029 expressing either p53DD or the control retroviral vec-
tor, 6 hr following treatment with doxorubicin (Dox; 0.75 mM). Induction of
p21CIP1 is inhibited by p53DD.
B: Puma and Noxa induction following p63 RNAi are not inhibited by p53DD
expression. JHU-029 cells expressing the control vector or p53DD were har-
vested 72 hr following treatment with a p63 shRNA-expressing lentivirus
(p63si) or the control lentiviral vector.
C: TAp73 induces Puma and Noxa in a p63-dependent manner in HNSCC
cells. JHU-029 cells expressing retroviral TAp73 or the control vector under-
went lentiviral infection as in B and were harvested at 72 hr for immunoblot.
D: PumaandNoxa induction following p63 RNAi require endogenous TAp73.
Stable pools of JHU-029 expressing a TAp73-directed shRNA (TAp73si) or the
control vector were infected with a p63 shRNA-expressing lentivirus or con-
trol vector and were harvested at 72 hr for immunoblot. Note that endoge-
nous p73 levels are unchanged following p63 RNAi.
E: Cell death following p63 RNAi is p53 independent but requires endoge-
nous TAp73. Quantitation of annexin V- and/or PI-positive JHU-029 cells
treated as in B (left graph) and D (right graph), harvested 96 hr following
p63 shRNA lentiviral (p63si) or control vector infection. Error bars show stan-
dard deviation for three independent experiments.50(Figure 5D). To test directly whether endogenous p73 is required
for cell death following loss of p63, we assayed the effect of p63
knockdown in cells in which p73 expression was ablated by
RNAi. We first generated lentiviral shRNA species directed
against the p73 N-terminal transactivation domain and infected
JHU-029 with this virus followed by brief drug selection. This se-
lected cell pool exhibited at least 75% knockdown of p73 com-
pared to control vector-infected cells (Figure 5D). Then we ex-
pressed the p63-directed shRNA in these cells. Remarkably,
p73 knockdown substantially and consistently abrogated the ef-
fects of p63 inhibition. Thus, in the absence of p73 we observed
little or no Puma induction, Noxa induction, or cell death as as-
sessed by annexin V/PI staining (Figures 5D and 5E). Therefore,
TAp73 is required for the apoptotic program elicited following
loss of p63. Together, these data suggest that p63 suppresses
a proapoptotic function of p73 in squamous carcinoma cells.
TAp73b is complexed to DNp63a in HNSCC cells
Several possible models could explain functional inhibition of
p73 by p63. We first examined whether p63 knockdown in-
creased expression of either the p73 mRNA or protein. No
change in the p73 mRNA was detected by QRT-PCR, and no
change in the p73 protein was evident following p63 knockdown
in either JHU-029 or JHU-011 (Figure 5D and data not shown).
The p63 and p73 proteins contain a highly homologous (>60%
identical) oligomerization domain, and they are reported to inter-
act physically when coexpressed (Chan et al., 2004; Davison
et al., 1999). Therefore, we tested the ability of ectopically
expressed DNp63a and TAp73b to interact by coimmunopre-
cipitation using antibodies directed against either protein. We
transfected DNp63a, TAp73b, or both proteins into U2OS oste-
osarcoma cells, which express little if any endogenous p63 and
p73. These two proteins bound one another quantitatively when
coexpressed in U2OS, even under stringent detergent condi-
tions (Figure 6A). These experiments also demonstrate that
the p63 and p73 antibodies used for these studies do not cross-
react (Figure 6A).
Next, we tested whether the endogenous DNp63a and
TAp73b proteins could be coimmunoprecipitated in JHU-029
cells. Endogenous TAp73b protein was readily detectable in ly-
sates following p63 IP, and endogenous DNp63a was coimmu-
noprecipitated using p73-specific antisera (Figure 6B). Thus, en-
dogenous DNp63a and TAp73b physically interact in HNSCC
cells. Similar results were obtained using either whole-cell ly-
sates (Figure 6B) or nuclear lysates (data not shown), in keeping
with the predominantly nuclear localization of both proteins.
We observed that the amount of coimmunoprecipitated
DNp63a following IP for p73 represented only a small fraction
of endogenous DNp63a, whereas a much larger fraction of en-
dogenous TAp73b was brought down by p63 IP. (Compare
the ratios of input to immunoprecipitated proteins in Figure 6B.)
These findings are consistent with the large molar excess of
DNp63a within the cell relative to TAp73b. Furthermore, they
suggested that a high fraction of cellular TAp73b is bound to
DNp63a. To address this issue directly, we immunodepleted ly-
sates from JHU-029 cells for DNp63a, then examined the frac-
tion of DNp63a versus TAp73b remaining in these lysates. We
achieved approximately 90% immunodepletion of endogenous
DNp63a (Figure 6C). Remarkably, the same lysate showed
approximately 90% depletion for TAp73b as compared to the
control (mock immunodepleted) lysate. These data suggestCANCER CELL JANUARY 2006
A R T I C L Ethat the vastmajority of TAp73bwithin the cell is complexedwith
DNp63a.
DNp63a inhibits p73-dependent transcription
through direct promoter binding
Together, our findings argue that TAp73b promotes apoptosis
following knockdown of DNp63a through activation of effector
genes includingPuma. Thismodel implies that TAp73b is a direct
transcriptional regulator of Puma and that p73-dependent acti-
vation of Puma is inhibited in the presence of DNp63a. To test
these two predictions, we examined p73-mediated regulation
of the Puma promoter. The human Puma promoter contains
two putative p53 family binding sites within a 500 bp region up-
stream of the major transcription start site; however, only one of
these sites is conserved in mouse (Yu et al., 2001). We used the
wild-type Puma promoter reporter (Yu et al., 2001), and in addi-
tion created a mutant reporter in which the critical consensus
residues within the evolutionarily conserved p53 family binding
site were changed (Figure 7A). As expected, transfection of
p53 significantly induced expression of the wild-type reporter,
while minimal induction of the mutant promoter was observed
(Figure 7B). Of note, expression of TAp73b, the major p73 pro-
tein expressed in JHU-029 cells, induced the reporter even
more strongly than p53. Induction by TAp73b requires the p53
family binding motif, as minimal induction of the mutant reporter
was observed (Figure 7B). These findings suggest that TAp73b,
Figure 6. P73 binds p63 in HNSCC cells
A: p63 and p73 coimmunoprecipitate (co-IP) when coexpressed. Immuno-
blots of U2OS cells transfected with plasmids encodingDNp63a or TAp73bas
shown, followed by IP using antibodies against the indicated proteins. Ten
percent of each lysate prior to IP (Input) is also shown. Note the absence
of antibody crossreactivity.
B: Endogenous p63 and p73 co-IP in HNSCCcells. Lysates from JHU-029 were
immunoprecipitated using preimmune sera (Pre) or antibodies against the
indicated proteins.
C: The vast majority of endogenous p73 in bound to p63. Lysates from JHU-
029 were immunodepleted with preimmune sera (Pre) or a-p63 antisera, fol-
lowed by immunoblot.CANCER CELL JANUARY 2006like p53, is a potent and direct regulator of Puma transcription.
We then tested the ability of DNp63a coexpression to inhibit
p73-mediated Puma promoter regulation. Coexpression of
DNp63a with TAp73b blocked p73-mediated transcription in
a dose-dependent manner (Figure 7C). Taken together, these
data imply that high-level DNp63a in squamous carcinoma cells
binds p73 to inhibit its transactivation of proapoptotic genes and
subsequent cell death.
Two possible models could explain inhibition of p73-depen-
dent transcription resulting from binding of DNp63a. DNp63a
could inhibit p73-dependent transactivation by an ‘‘off-pro-
moter’’ mechanism involving exclusively sequestration of p73
protein. Alternatively, DNp63a-containing complexes might be
localized to the Puma promoter, suggesting that DNp63a also
functions as a direct repressor of Puma transcription. To distin-
guish between these possibilities, we performed chromatin im-
munoprecipitation (ChIP) for p63 in JHU-029 cells. We observed
strong enrichment of Puma promoter sequences relative to
a control genomic locus following ChIP for p63 (Figure 7D). In
contrast, we do not detect Puma promoter sequences following
IP using preimmune sera. The findings argue that DNp63a func-
tions to repress Puma transcription through both its physical in-
teraction with p73 and its direct binding to the Puma promoter.
Under normal growth conditions, we detect little if any enrich-
ment for Puma promoter sequences following ChIP using p73-
specific antibodies in JHU-029 cells, suggesting that most com-
plexes localized to this promoter are DNp63a homo-tetramers.
Our model predicts, however, that p73 should be recruited to
the Puma promoter following knockdown of p63. To test this
possibility, we performed ChIP using JHU-029 cells shown in
Figure 5C that express p73 and that induce Puma in a p63-
dependent manner. We find limited p73 on the Puma promoter
in the presence of p63, but we observe a significant increase in
p73 localization following p63 knockdown using either of two
p63-directed shRNA species (Figure 7E). These findings are
consistent with the large increase in Puma expression that we
observe following p63 knockdown in these cells (Figure 5C).
All together, these data strongly support our model that in
HNSCC cells p63 suppresses p73, which is recruited to the
Puma promoter in the absence of p63 to activate an apoptotic
program.
Bcl-2 expression abrogates the requirement for DNp63a
overexpression in HNSCC cells
While themajority ofHNSCC tumors andcell lines express p63at
high levels, aminority exhibit little or no p63 expression (Hu et al.,
2002; Sniezek et al., 2004; Weber et al., 2002). Since our data
demonstrate that HNSCC cells undergo apoptosis in the ab-
sence of a p63-mediated survival signal, it seemed that cells
with little or no p63 must somehow circumvent the requirement
for p63 expression. To investigate this possibility, we first as-
sayed p63 expression in a well-characterized panel of HNSCC
tumor-derived cell lines (Richtsmeier and Carey, 1987; Scher
et al., 1993). Of seven HNSCC cell lines initially tested, five
showed high-levelDNp63a protein expression (at levels compa-
rable to those in JHU-029 and JHU-011), while two showed little
or no DNp63a expression (Figure 8A). We then tested p73 ex-
pression in all these cell lines, reasoning that the absence of
p73might explain cell survival in the absence of p63 expression.
Surprisingly, all these cell lines express TAp73b at nearly the
same level as in JHU-029 (data not shown). Since we had51
A R T I C L EFigure 7. DNp63a blocks Puma transcriptional
regulation by TAp73b
A: Schematic representation of the human
Puma promoter. The conserved mammalian
p53 consensus binding site (p53 BS; black box)
is located between alternate exons 1a and 1b
(white boxes). Critical residues for p53 family
binding (asterisks) were changed (underlined)
to create a mutant site (p53 mut-BS).
B: Potent transactivation of the Puma reporter by
TAp73b requires the p53 binding site. A 200 bp
fragment containing the Puma p53 BS was
used to demonstrate luciferase reporter activa-
tion following cotransfection with the indicated
expression plasmids in Saos-2 cells. Values shown
are relative to the control vector and are nor-
malized for transfection efficiency. Error bars
show the standard error for three independent
experiments.
C: DNp63a blocks Puma transactivation by
TAp73b. Puma luciferase reporter activation fol-
lowing cotransfection with DNp63a and TAp73b
at the indicated molar ratios is shown, normal-
ized as in B. The amount of transfected TAp73b
is the same in each case.
D: p63 is localized to the Puma promoter in
HNSCC cells. PCR of the Puma p53 BS region
(Puma) following ChIP of crosslinked JHU-029 ly-
sates, using preimmune sera (Pre) or a-p63 sera.
PCR for a nonspecific genomic locus (NS) is
shown as an additional specificity control.
E: P73 is recruited to the Puma promoter follow-
ing knockdown of p63. JHU-029 cells expressing
TAp73 were infected with the lentiviral vector or
with p63 shRNA-expressing lentivirus (p63si),
then were subjected to ChIP 48 hr later using
anti-p73 antibody (a-p73), followed by PCR as
in D. ChIP using isotype-matched antibody
(Iso), and PCR for a nonspecific genomic locus
(NS) serve as negative controls, while PCR of
input total genomic DNA (Inp) controls for PCR
efficiency.identified proapoptotic bcl-2 family proteins as criticalmediators
of death following loss of p63, we hypothesized that overexpres-
sion of bcl-2 itself might provide a compensatory survival signal.
In agreement with this possibility, we found that both of the cell
lines lacking DNp63a expression exhibited high levels of bcl-2,
while those expressing DNp63a showed low or no bcl-2 expres-
sion (Figure 8A). To extend these results, we obtained a second
panel of tumor-derived HNSCC cell lines (Heo et al., 1989). As in
our initial panel, a striking inverse correlation between DNp63a
and bcl-2 levels was observed. Cells that showed high levels of
DNp63a did not express bcl-2, while those with little or no
DNp63a expression had robust bcl-2 levels (Figure 8B). These
findings imply that upregulation of endogenous bcl-2 may be
a mechanism to subvert the requirement for p63 expression in
HNSCC cells.
To determine directly whether bcl-2 expression conveyed
survival on HNSCC cells lacking DNp63a, we tested the effect
of constitutive bcl-2 expression in JHU-029 cells. We first gen-
erated stable pools of JHU-029 expressing bcl-2 via retroviral
infection followed by brief drug selection. We then examined
the effect of p63 knockdown in these cells compared to control
retroviral vector-expressing cells. We observed a dramatic res-
cue of cell death following p63 knockdown in cells expressing
bcl-2 versus the control vector, as evidenced by diminished
PARPcleavage (Figure 8C) and annexinV/PI staining (Figure 8D).52Consistent with our model, the p73-dependent transcriptional
program is still intact following bcl-2 expression, as both
Puma and Noxa proteins were still induced following p63 loss
in the presence of bcl-2 (Figure 8C). Together, these data are
consistent with a role for DNp63a in mediating a survival effect
that contributes to the pathogenesis of HNSCC, and that can
be superseded by high-level bcl-2 expression in the minority
of HNSCC cases that lack p63 expression.
Discussion
We find that DNp63a is significantly overexpressed in human
HNSCC cells relative to normal epidermal cells, consistent
with the large number of pathologic studies demonstrating
high p63 expression in HNSCC.While p63 is essential for normal
epithelial development in both mice and humans, precisely how
p63 might contribute to the pathogenesis of HNSCC remains
uncertain. Here, we show that endogenous DNp63a is required
for the survival of tumor cells by virtue of its ability to suppress
p73-dependent apoptosis. Ablating p63 expression by RNAi
triggers induction of Puma, Noxa, and apoptotic cell death.
While these events are p53 independent, they all require trans-
activating isoforms of p73. DNp63a could conceivably inhibit
the activity of p73 by a variety of mechanisms, given the amino
acid sequence homology within both the DNA binding andCANCER CELL JANUARY 2006
A R T I C L Eoligomerization domains of these two p53 family members. We
find that virtually all endogenous p73 is complexed to endoge-
nous DNp63a within HNSCC cells. In addition, p63 itself binds
the Puma promoter, and while we detect little if any p73 on
the Puma promoter in the presence of p63, p73 relocalizes to
this promoter following p63 knockdown. Relocalization of p73,
Puma induction, and PARP cleavage all occur within 48 hr of len-
tiviral infection. This time interval presumably reflects the time
required for DNp63a degradation, for release of p73, and finally
for assembly of an active p73-containing transcriptional com-
plex at the Puma promoter. Together, our findings support the
view that endogenous DNp63a suppresses the proapoptotic
activity of p73 both through its direct association with p73,
and through direct repression of p73-dependent transcription.
Early studies involving ectopic overexpression of DNp63a
suggested that it might serve to inhibit apoptosis mediated by
both p53 and p73 (Yang et al., 1998). Therefore, it was initially
speculated that increased DNp63a expression might obviate
the need for p53 mutation in HNSCC. However, reports have
varied as to whether p53 mutation and p63 overexpression
are inversely correlated in HNSCC (Choi et al., 2002; Hibi
et al., 2000; Sniezek et al., 2004; Weber et al., 2002). Our finding
that DNp63a mediates a survival effect that is independent of
p53 may provide an explanation for the lack of a consistent cor-
relation. Our data might also explain in part the finding that
Figure 8. Bcl-2 upregulation abrogates the requirement for p63 expression in
HNSCC
A: Bcl-2 expression correlates inversely with p63 expression in HNSCC cells.
Immunoblots were performed using lysates from the indicated HNSCC tu-
mor-derived cell lines.
B: A second panel of HNSCC tumor-derived cell lines supports the pattern
observed in A.
C: Bcl-2 expression blocks PARP cleavage but not PumaandNoxa induction
following p63 inhibition. JHU-029 cells expressing retroviral bcl-2 or the con-
trol vector were harvested 72 hr following treatment with a p63 shRNA-
expressing lentivirus (p63si) or the control lentiviral vector.
D: Bcl-2 expression blocks apoptosis following p63 inhibition. Quantitation of
annexin V- and/or PI-positive JHU-029 cells treated as in C, harvested 96 hr
following p63 shRNA lentiviral (p63si) or control vector infection. Error bars
show standard deviation for three independent experiments.CANCER CELL JANUARY 2006mutations in either p73 or PUMA are very uncommon in HNSCC
cells (Hoque et al., 2003; Weber et al., 2002). We find that p73 is
inactivated by DNp63a overexpression in the majority of such
cancers, and its downstream effectors are neutralized by over-
expression of bcl-2 in a significant minority.
Our findings also shed light on previous studies demonstrat-
ing that p73 is a critical mediator of cell death following chemo-
therapy in HNSCC (Bergamaschi et al., 2003; Irwin et al., 2003).
These studies demonstrated that p73 is modestly induced fol-
lowing DNA-damaging agents. Of note, we and others have ob-
served that DNp63a itself is dramatically downregulated follow-
ing DNA damage (Liefer et al., 2000). Thus, p73-mediated cell
death following DNA damage may represent the cumulative ef-
fect of increased p73 levels and decreased p63-mediated inhi-
bition. As a pilot experiment to test this possibility, we examined
the effect of p73 loss on cell survival following treatment with the
chemotherapeutic agent cisplatin, which rapidly downregulates
p63 expression (Fomenkov et al., 2004). For these experiments,
we used JHU-029 cells in which TAp73 expression was ablated
by RNAi (Figure 5D). We found that loss of TAp73 indeed atten-
uated cellular sensitivity to cisplatin (Figure S3). These findings
support a role for p73 in DNA damage-induced cell death follow-
ing downregulation of p63. This pathway may be restricted to
particular cell types, however, since genetic deletion of p73
does not affect sensitivity to ionizing radiation in murine T cells
(Senoo et al., 2004). Posttranslational modification of p73 fol-
lowing DNA damage is also thought to play a role in its activation
and promoter selectivity (Strano et al., 2005). This fact may ex-
plain differences in proapoptotic genes induced by p73 follow-
ing DNA damage versus those we find induced following inhibi-
tion of p63 by RNAi (Bergamaschi et al., 2003; Strano et al.,
2005). Consistent with our findings, a prior study found that
overexpression of p73 in the absence of DNA damage leads
to induction of endogenous Puma mRNA and protein (Melino
et al., 2004).
Although our studies show that p73 is necessary for the apo-
ptotic program activated following loss of p63, our findings do
not rule out additional mechanisms by which p63 may promote
tumor cell survival. Indeed, one recent study identified the insu-
lin-like growth factor binding protein 3 (IGFBP-3) as a potential
transcriptional target of p63 in HNSCC (Barbieri et al., 2005).
This study did not directly address a potential contribution of
IGFBP-3 to HNSCC survival; however, p63 is likely to regulate
a number of factors that contribute to the pathogenesis of these
tumors. Nevertheless, we find that bcl-2 expression rescues
cells from death following loss of p63 and is inversely correlated
with p63 in HNSCC cells. These observations are consistent
with a primary role for p63 as a suppressor of the mitochondrial
apoptotic pathway downstream of p73.
A minority of HNSCC tumors exhibit low or absent p63 ex-
pression, and our data begin to address their particular biology.
Rather than evade apoptosis via loss of p73, these tumors may
instead upregulate bcl-2, which we show to be a potent sup-
pressor of the p63-dependent apoptotic program. A recently re-
ported mouse tumor model may be of use in furthering our un-
derstanding of such p63-low tumors. This model involves mice
engineered for p63 heterozygosity, 10% of which develop squa-
mous carcinomas characterized by loss of the remaining p63 al-
lele (Flores et al., 2005). Like human tumors, these tumors do not
commonly exhibit loss of p73, even in a p73 heterozygous back-
ground. It will therefore be of interest to determine whether53
A R T I C L Eupregulation of bcl-2 is a cooperating event observed during
tumorigenesis in this model.
Finally, our data may in part explain previously observed
prognostic correlations involving p63 and bcl-2. Head and
neck cancers are commonly treated with a combination of
DNA-damaging agents, including radiation and/or chemother-
apy. For cancers that express DNp63a, its downregulation
and the subsequent activation of p73 may be important media-
tors of a favorable response to treatment (Massion et al., 2003).
In contrast, upregulation of bcl-2 and the corresponding loss of
DNp63a may signify tumors that are resistant to the proapop-
totic effect of these treatment modalities. In fact, several studies
support the use of bcl-2 expression as a marker of poor re-
sponse to standard radiation and chemotherapy in HNSCC
(Nix et al., 2005; Ogawa et al., 2003). Thus, tumors that have cir-
cumvented the requirement for p63-mediated survival may ex-
hibit resistance to common cancer treatments, making them
good candidates for alternative therapeutic approaches.
Experimental procedures
Cell lines
The HNSCC cell lines designated JHU were the generous gift of David
Sidransky, MD, Johns Hopkins University, Baltimore, MD (Richtsmeier and
Carey, 1987; Scher et al., 1993), and those designated PCI were the gener-
ous gift of Robert Ferris, MD, Ph.D., University of Pittsburgh Cancer Institute,
Pittsburgh, PA (Heo et al., 1989).
Lentiviral and retroviral production and infection
The shRNA lentiviral constructs were created by transferring the U6 pro-
moter-shRNA cassette into a lentiviral backbone. High-titer amphotrophic
retroviral and lentiviral stocks were generated as described (Ellisen et al.,
2001; Shin et al., 2004; Rubinson et al., 2003). The p63si-1 lentiviral vector
used in some experiments was the generous gift of Dr. William Hahn. The tar-
geted sequences for p63 were 50-GGGTGAGCGTGTTATTGATGCT-30 and
50-GAGTGGAATGACTTCAACTTT-30. The targeted sequence for TAp73
was 50-GGATTCCAGCATGGACGTCTT-30. Further details are available in
the Supplemental Data.
QRT-PCR analysis
First-strand cDNA was synthesized from total RNA using random hexamer
primers and the SuperScript II system for RT-PCR (Invitrogen). Gene expres-
sion levels were measured by real-time QRT-PCR using the iQ SYBR Green
Supermix reagent (Bio-Rad) and an Opticon real-time PCR detector system
(MJ Research). Data analysis was performed using Opticon Monitor Analysis
Software V1.08 (MJ Research). The expression of each gene was normalized
to GAPDH as a reference, and relative levels were calculated from a 4-point
standard curve. All experiments were performed in triplicate. Further details
and primer sequences are available in the Supplemental Data.
Luciferase promoter reporter and apoptosis assays
Saos-2 cells were seeded in 24-well plates and were transfected with the in-
dicated expression construct, reporter plasmid, and SV40-renilla control
vector, and lysates were analyzed at 48 hr using the Dual Luciferase Reporter
Assay system (Promega) according to the manufacturer’s recommenda-
tions. Further details are available in the Supplemental Data. Apoptotic cell
death was determined using the BD ApoAlert annexin V-FITC Apoptosis
Kit (BD Biosciences) according to the manufacturer’s instructions, and cells
were analyzed on a FACSCalibur flow cytometer using CellQuest Pro soft-
ware (BD Biosciences).
Immunoprecipitation and ChIP
Transfected U2OS cells or untransfected JHU-029 cells were lysed on ice in
lysis buffer (0.75% NP-40, 1 mM DTT, and protease inhibitors in PBS). Pre-
cleared lysates (1.0 mg) were incubated with either 2.0 mg/sample of anti-
p63 polyclonal antibody (H-129, Santa Cruz) or 1.0 mg/sample of anti-p73
monoclonal antibody (Ab-1 and Ab-2, CalBiochem) for 2 hr at 4ºC, and54immunocomplexes were precipitated using protein A or protein G Sepharose
(both from Amersham Biosciences), then washed four times with lysis buffer
prior to analysis by SDS-PAGE. ChIP assays were performed essentially as
described (Meluh and Broach, 1999), with modifications as detailed in the
Supplemental Data. ‘‘Input’’ templates were purified from 10% of the original
lysates in parallel with the eluted IP products. PCRwas carried out using 10%
of the IP product with primers spanning the conserved p53 family binding
motif within the Puma promoter or targeting the nonspecific (loricrin) gene.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
three supplemental figures, and one supplemental table and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/1/
45/DC1/.
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